Table 5.

Dopaminergic medications and supplement use. NA = not answered (missing)

Item	Fox Insight	PPMI	PDBP	Sig. diff	Post-hoc effect sizes
Levodopa	77.55% (9792/12626)	0% (0/422)	78.64% (508/646)
Dopamine agonist	32.08% (4051/12626)	0% (0/422)	49.07% (317/646)	*	FI vs. PDBP: 0.077
Other PD med	33.71% (4256/12626)	0% (0/422)	64.71% (418/646)	*	FI vs. PDBP: 0.139
Vitamin	66.67% (8415/12622)	16.82% (71/422)	38.54% (249/646)	*	FI vs. PDBP: 0.127
Qoenzyme q10	19% (2398/12622)	15.17% (64/422)	6.81% (44/646)	*	FI vs. PDBP: 0.067
Stratified by disease duration
Levodopa
0–2 years	59.71% (2316/3879)	0% (0/408)	56.03% (79/141)	*	FI vs. PPMI: 0.351
2–5 years	77.72% (2969/3820)	0% (0/14)	75% (123/164)	*	FI vs. PPMI: 0.11
5–10 years	90.15% (2737/3036)		82.89% (155/187)
10+ years	93.6% (1770/1891)		98.05% (151/154)
Dopamine agonist
0–2 years	20.01% (776/3879)	0% (0/408)	29.79% (42/141)	*	FI vs. PPMI: 0.151
2–5 years	30.21% (1154/3820)	0% (0/14)	43.9% (72/164)
5–10 years	42.36% (1286/3036)		60.96% (114/187)	*	FI vs. PDBP: 0.084
10+ years	44.16% (835/1891)		57.79% (89/154)
Other PD med
0–2 years	20.98% (814/3879)	0% (0/408)	46.81% (66/141)	*	FI vs. PPMI: 0.155
					FI vs. PDBP: 0.112
2–5 years	34.4% (1314/3820)	0% (0/14)	58.54% (96/164)	*	FI vs. PDBP: 0.097
5–10 years	42.69% (1296/3036)		74.33% (139/187)	*	FI vs. PDBP: 0.146
10+ years	44% (832/1891)		75.97% (117/154)	*	FI vs. PDBP: 0.166
Vitamin
0–2 years	67.83% (2633/3882)	16.91% (69/408)	37.59% (53/141)	*	FI vs. PPMI: 0.308
					FI vs. PDBP: 0.116
2–5 years	66.45% (2541/3824)	14.29% (2/14)	42.68% (70/164)	*	FI vs. PDBP: 0.096
5–10 years	66.94% (2031/3034)		41.71% (78/187)	*	FI vs. PDBP: 0.121
10+ years	64.29% (1210/1882)		31.17% (48/154)	*	FI vs. PDBP: 0.177
Coenzyme q10
0–2 years	20.94% (813/3882)	14.22% (58/408)	6.38% (9/141)	*	FI vs. PDBP: 0.062
2–5 years	19.87% (760/3824)	42.86% (6/14)	9.15% (15/164)
5–10 years	17.24% (523/3034)		6.95% (13/187)
10+ years	16.05% (302/1882)		4.55% (7/154)